Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose

NCT01384734 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT01384734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01384734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Completed
Start date
July 26, 2011
Completion date
May 12, 2017
Enrollment
254 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus